Emergent Biosolutions
EBS
263 hedge funds and large institutions have $2.15B invested in Emergent Biosolutions in 2018 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 103 increasing their positions, 99 reducing their positions, and 30 closing their positions.
4% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 99
0.37% more ownership
Funds ownership: 85.09% → 85.45% (+0.37%)
3% less capital invested
Capital invested by funds: $2.21B → $2.15B (-$61M)
3% less funds holding
Funds holding: 272 → 263 (-9)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
27% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 30
39% less call options, than puts
Call options by funds: $212K | Put options by funds: $348K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$47M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$14.5M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$13M |
| 4 |
State Street
Boston,
Massachusetts
|
+$12.5M |
| 5 |
Renaissance Technologies
New York
|
+$10.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$17.8M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
-$14M |
| 3 |
Prudential Financial
Newark,
New Jersey
|
-$12.3M |
| 4 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
-$10.5M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$9.4M |
EBS Hedge Fund Activity: Q2 2018 in Review
263 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q2 2018, worth a combined $2.15B — down 2.8% from $2.21B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of EBS and 22 opened new positions — a net loss of 8 holders — while 99 trimmed existing stakes and 103 added.
The largest buyer was BlackRock, adding an estimated $47M. The largest seller was Millennium Management, cutting an estimated $17.8M.
- 263 institutional investors held Emergent Biosolutions (EBS) as of Q2 2018, down from 272 in Q1 2018.
- Funds reported $2.15B of Emergent Biosolutions stock for Q2 2018, down 2.8% quarter-over-quarter.
- 22 funds opened new Emergent Biosolutions positions in Q2 2018 and 30 closed out, a net change of -8 holders.
- The largest Emergent Biosolutions buyer in Q2 2018 was BlackRock, an estimated $47M added.
- The largest Emergent Biosolutions seller in Q2 2018 was Millennium Management, an estimated $17.8M sold.
Based on aggregated 13F filings for Q2 2018.